Skip to main content

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

Written by Customer Service on . Posted in Public Companies.


Affimed researchers served as co-authors on an abstract for RO7297089 with scientific collaborators from Genentech, a member of the Roche GroupAffimed will host a live teleconference at 8am Eastern to discuss the abstracts and recent corporate developmentsHeidelberg, Germany, May 15, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that data from two studies investigating innate cell engagers developed from its fit-for-purpose ROCK® platform have been accepted for e-poster presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held on June 22-24, 2020. Affimed researchers served as authors on abstract #5659 and co-authors on abstract #6987 with scientific collaborators from Genentech, a member of the Roche Group, on the respective abstracts that include the following:Title: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignanciesAbstract: 5659Authors: Uwe Reusch, Michael Damrat, Susanne Wingert, Stefan H.J. Knackmuss, Thomas Mueller, Ivica Fucek, Ute Schniegler-Mattox, Kristina Ellwanger, Torsten Haneke, Andras Strassz, Wolfgang Fischer, Erich Rajkovic, Michael Tesar. Affimed GmbH, Heidelberg, GermanyPoster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.Title: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myelomaAbstract:  6987Authors: Satoko Kakiuchi-Kiyota, Melissa Schutten, Adeyemi O. Adedeji, Hao Cai, Robert Hendricks, Luna Liu, Sivan Cohen, Aaron Fullerton, Nicholas Corr, Lanlan Yu, Denise de Almeida-Nagata, Shelly Zhong, Michael Dillon, Christoph Spiess, Steve Leong, Bing Zheng. Genentech Inc.; Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Thorsten Ross. Affimed; Andy Polson, Ayse Meric Ovacik. Genentech Inc.Poster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.More details about the programs for the AACR Virtual Annual Meeting II are available online at www.aacr.org.Conference Call InformationAffimed will host a live teleconference today, Friday May 15th at 8am Eastern to discuss the abstracts and recent corporate developments. The teleconference details will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts_cp/, and a replay of the teleconference will be accessible at the same link for 30 days following the call.About Affimed N.V.Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company’s initial clinical program, AFM13 for CD30-positive lymphomas, is currently enrolling patients for a registration-directed study in relapsed/refractory peripheral T cell lymphoma.  For more information, please visit www.affimed.com.   Investor ContactSolebury Trout, Thomas Hoffmann
Phone: 646-378-2931
Email: thoffmann@troutgroup.com or IR@affimed.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.